Scarica l'app Stockscreener
6.19
4.48%
-0.29
Precedente Chiudi:
$6.48
Aprire:
$6.6
Volume 24 ore:
823.86K
Relative Volume:
0.76
Capitalizzazione di mercato:
$546.73M
Reddito:
$73.48M
Utile/perdita netta:
$-108.30M
Rapporto P/E:
-2.7511
EPS:
-2.25
Flusso di cassa netto:
$-67.17M
1 W Prestazione:
-2.83%
1M Prestazione:
-5.21%
6M Prestazione:
+26.58%
1 anno Prestazione:
+152.65%
Intervallo 1D:
$6.115
$6.6691
Intervallo di 1 settimana:
$6.115
$6.6691
Portata 52W:
$2.50
$7.79
Personalis Inc Stock (PSNL) Company Profile
Nome
Personalis Inc
Settore
Industria
Telefono
650-752-1300
Indirizzo
6600 DUMBARTON CIRCLE, FREMONT, CA
Confronta PSNL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
6.19 | 562.63M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
414.75 | 164.16B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
190.05 | 146.60B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
514.61 | 42.89B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.99 | 35.02B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
160.63 | 28.16B | 15.50B | 1.33B | 2.16B | 7.34 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-15 | Iniziato | Guggenheim | Buy |
| 2025-03-17 | Iniziato | Craig Hallum | Buy |
| 2023-02-06 | Aggiornamento | Needham | Hold → Buy |
| 2022-01-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-11-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Downgrade | Needham | Buy → Hold |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-20 | Reiterato | Needham | Buy |
| 2021-05-06 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2021-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-12 | Reiterato | Needham | Buy |
| 2020-11-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-08-27 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2019-09-26 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Iniziato | BofA/Merrill | Neutral |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Morgan Stanley | Overweight |
| 2019-07-15 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Personalis Inc Borsa (PSNL) Ultime notizie
What drives Personalis Inc. stock priceMassive profits - Autocar Professional
Is Personalis Inc. a good long term investmentFree Stock Market Forecast Reports - Autocar Professional
Personalis Inc. Stock Analysis and ForecastExplosive trading opportunities - Jammu Links News
What analysts say about Personalis Inc. stockFree Wealth Management Insights - Jammu Links News
Personalis Strengthens Leadership: New VP Gets $631K Stock Option Package in Precision Oncology Push - Stock Titan
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PSNL Stock News - GuruFocus
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer - Insider Monkey
From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine - Benzinga
How Personalis Inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser
Why Personalis Inc. stock attracts strong analyst attentionFree Insider Trading Tips - Newser
What makes Personalis Inc. stock price move sharplyFree Investment Group - Newser
Personalis (NASDAQ:PSNL) Pulls Back 14% This Week, but Still Delivers Shareholders Splendid 284% Return Over 1 Year - 富途牛牛
Personalis, Inc. (PSNL) Stock Analysis: Navigating a 5.50% Revenue Growth Amidst Volatility - DirectorsTalk Interviews
Personalis (PSNL) Expands Partnership with Tempus AI for Cancer Detection - GuruFocus
Personalis and Tempus: Pioneering the Future of Colorectal Cancer Care Through Precision Diagnostics - AInvest
Personalis expands Tempus deal to include colorectal cancer testing - Seeking Alpha
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients - businessnewsthisweek.com
Personalis and Tempus extend cancer detection collaboration to 2029 By Investing.com - Investing.com South Africa
Personalis and Tempus: A Cancer Detection Breakthrough with Multi-Billion-Dollar Implications - AInvest
Personalis extends Tempus agreement to add colorectal cancer indication By Investing.com - Investing.com South Africa
Personalis and Tempus extend cancer detection collaboration to 2029 - Investing.com Australia
Personalis Expands Tempus Strategic Collaboration to Bring Ultra - GuruFocus
Personalis extends Tempus agreement to add colorectal cancer indication - Investing.com
Personalis Expands Agreement with Tempus AI for Cancer Test - TipRanks
Personalis Expands Tempus AI Collaboration to Include Colorectal Cancer - HIT Consultant
Personalis Expands Tempus AI Collaboration to Include Colorectal Cancer Detection - MarketScreener
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-S Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients - MarketScreener
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains? - MSN
Supernus Pharmaceuticals (NASDAQ:SUPN) & Personalis (NASDAQ:PSNL) Financial Comparison - Defense World
Personalis, Inc.(NasdaqGM: PSNL) added to Russell Small Cap Completeness Index - MarketScreener
Personalis, Inc.(NasdaqGM: PSNL) added to Russell 3000 Index - MarketScreener
Personalis Inc Azioni (PSNL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Personalis Inc Azioni (PSNL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Moore Stephen Michael | SVP and Chief Legal Officer |
May 16 '25 |
Sale |
4.95 |
1,675 |
8,291 |
64,200 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
May 16 '25 |
Sale |
4.95 |
910 |
4,504 |
124,957 |
| Tachibana Aaron | CFO AND COO |
Jan 28 '25 |
Sale |
5.79 |
708 |
4,099 |
166,390 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Jan 28 '25 |
Sale |
5.79 |
519 |
3,005 |
123,367 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Dec 16 '24 |
Sale |
3.82 |
4,834 |
18,466 |
123,886 |
| Moore Stephen Michael | SVP and Chief Legal Officer |
Dec 16 '24 |
Sale |
3.82 |
1,513 |
5,780 |
65,875 |
| Tachibana Aaron | CFO AND COO |
Dec 16 '24 |
Sale |
3.82 |
6,865 |
26,224 |
167,098 |
| Tachibana Aaron | CFO AND COO |
Nov 18 '24 |
Sale |
3.79 |
1,307 |
4,954 |
173,963 |
| Moore Stephen Michael | SVP and Chief Legal Officer |
Nov 18 '24 |
Sale |
3.79 |
1,693 |
6,416 |
67,388 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Nov 18 '24 |
Sale |
3.79 |
921 |
3,491 |
128,720 |
3.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):